Angel Cooper
Pfizer (United States)(US)
Publications by Year
Research Areas
Antibiotics Pharmacokinetics and Efficacy, Antibiotic Resistance in Bacteria, Pneumonia and Respiratory Infections, Microbial infections and disease research, Antibiotic Use and Resistance
Most-Cited Works
- → A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae(2008)101 cited
- → Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin(2008)96 cited
- → Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis(2013)94 cited
- → Safety and Efficacy of Intravenous Tigecycline in Subjects with Secondary Bacteremia: Pooled Results from 8 Phase III Clinical Trials(2009)94 cited
- → In vitro activity of danofloxacin, tylosin and oxytetracycline against mycoplasmas of veterinary importance(1993)78 cited
- → Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia(2006)62 cited
- → Pharmacokinetics-Pharmacodynamics of Tigecycline in Patients with Community-Acquired Pneumonia(2011)52 cited
- → Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial(2010)47 cited
- → Tigecycline Population Pharmacokinetics in Patients with Community- or Hospital-Acquired Pneumonia(2010)39 cited
- → Efficacy of danofloxacin in the therapy of experimental mycoplasmosis in chicks(1992)29 cited